Mitchel L. Zoler, PhD July 11, 2023 A smartphone-based app designed to deliver cognitive behavioral therapy (CBT) to adults with type 2 diabetes received marketing approval as a class II medical device from the US Food and Drug Administration (FDA) on July 10, becoming the first digital behavioral therapeutic device for people with diabetes to receive this designation for US patients. Better...